BOSTON, July 30, 2024 (GLOBE NEWSWIRE) — CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that Company’s Management will participate in a fireside chat at the Canaccord Genuity 44th Annual Growth Conference, to be held in Boston, MA, and participate in one-on-one investor meetings.
Presentation Details
Format: Fireside Chat
Date: Tuesday, August 13, 2024
Time: 12:30 PM ET
Webcast Link: https://wsw.com/webcast/canaccord98/crvo/2485318
The webcast of the fireside chat will be accessible in the Investors section of the CervoMed website https://www.cervomed.com/.
About CervoMed
CervoMed Inc. (the “Company”) is a clinical-stage company focused on developing treatments for age-related neurologic disorders. The Company is currently developing neflamapimod, an investigational, orally administered small molecule brain penetrant that inhibits p38MAP kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that causes disease in DLB and certain other major neurological disorders. Neflamapimod is currently being evaluated in a Phase 2b study in patients with DLB.
Investor Contact:
PJ Kelleher
LifeSci Advisors
Investors@cervomed.com
617-430-7579
Industry Leaders Dave Fabry, Ph.D. and Douglas L. Beck, Au.D. share insights to help providers…
VANCOUVER, BC, Aug. 8, 2024 /PRNewswire/ -- EmeTerm® Smart uses patented hybrid technology to seamlessly…
Innovative solution from a women-owned business seamlessly integrates the advantages of self-funding into fully-insured supplemental…
OTTAWA, ON, Aug. 8, 2024 /PRNewswire/ - On August 14, Claigan Environmental Inc. (www.claigan.com) will…
CHICAGO, Aug. 8, 2024 /PRNewswire/ -- The global Label-Free Detection Market is expected to grow from…
One of the first structures of its kind in the neighborhood, the building will be…